TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,497,861 | +43.4% | 167,546 | +146.4% | 0.00% | – |
| Q2 2023 | $1,044,265 | -80.8% | 67,986 | -71.8% | 0.00% | -100.0% |
| Q1 2023 | $5,425,578 | +700.2% | 241,244 | +761.8% | 0.00% | – |
| Q2 2022 | $678,000 | -48.3% | 27,994 | -45.0% | 0.00% | – |
| Q1 2022 | $1,312,000 | +9.2% | 50,900 | +31.5% | 0.00% | – |
| Q4 2021 | $1,202,000 | +375.1% | 38,704 | +271.5% | 0.00% | – |
| Q3 2021 | $253,000 | -79.0% | 10,418 | -87.4% | 0.00% | – |
| Q2 2021 | $1,207,000 | +402.9% | 82,744 | +761.1% | 0.00% | – |
| Q1 2021 | $240,000 | -54.1% | 9,609 | -49.9% | 0.00% | – |
| Q4 2020 | $523,000 | – | 19,177 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |